Literature DB >> 8633650

The safety of calcium channel blockers in human pregnancy: a prospective, multicenter cohort study.

L A Magee1, B Schick, A E Donnenfeld, S R Sage, B Conover, L Cook, P R McElhatton, M A Schmidt, G Koren.   

Abstract

OBJECTIVE: Our purpose was to examine the potential teratogenicity of calcium channel blockers. STUDY
DESIGN: Six teratogen information services prospectively collected and followed up 78 women with first-trimester exposure to calcium channel blockers. Pregnancy outcome was compared (by paired t text of chi2 analysis) with that of a control group matched for maternal age and smoking.
RESULTS: There was no increase in major malformation (2/66=3.0% [calcium channel blockers] vs 0% [nonteratogenic controls], p=0.27); a fivefold increase was ruled out (baseline 2%, alpha = 0.05, beta = 0.20). The defects reported were attributable to maternal diabetes or coingestion of teratogens. The increase in preterm delivery 28% [calcium channel blockers] vs 9% [nonteratogenic controls], p=0.003), attributed to maternal disease by stepwise regression, was the most important factor responsible for the observed decrease in birth weight (mean -334 gm vs nonteratogenic controls, p=0.08).
CONCLUSION: This study suggests that calcium channel blockers do not represent a major teratogenic risk.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8633650     DOI: 10.1016/s0002-9378(96)70307-1

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  23 in total

1.  [Heart diseases in pregnancy].

Authors:  Vera Regitz-Zagrosek; Christa Gohlke-Bärwolf; Annette Geibel-Zehender; Markus Haass; Harald Kaemmerer; Irmtraut Kruck; Christoph Nienaber
Journal:  Clin Res Cardiol       Date:  2008-09       Impact factor: 5.460

Review 2.  Pharmacokinetic changes during pregnancy and their clinical relevance.

Authors:  R Loebstein; A Lalkin; G Koren
Journal:  Clin Pharmacokinet       Date:  1997-11       Impact factor: 6.447

3.  Maternal hypertension with nifedipine treatment associated with a higher risk for right-sided obstructive defects of the heart: a population-based case-control study.

Authors:  Melinda Csáky-Szunyogh; Attila Vereczkey; Balázs Gerencsér; Andrew E Czeizel
Journal:  Heart Asia       Date:  2014-01-23

Review 4.  Assessing the safety of drugs in pregnancy: the role of prospective cohort studies.

Authors:  C Irl; J Hasford
Journal:  Drug Saf       Date:  2000-03       Impact factor: 5.606

Review 5.  Cluster Headache: Special Considerations for Treatment of Female Patients of Reproductive Age and Pediatric Patients.

Authors:  Juliana VanderPluym
Journal:  Curr Neurol Neurosci Rep       Date:  2016-01       Impact factor: 5.081

Review 6.  Treating hypertension in women of child-bearing age and during pregnancy.

Authors:  L A Magee
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 7.  Intracranial haemorrhage in pregnancy.

Authors:  Jacob M Fairhall; Marcus A Stoodley
Journal:  Obstet Med       Date:  2009-11-30

Review 8.  Drug treatment of hypertension in pregnancy.

Authors:  Catherine M Brown; Vesna D Garovic
Journal:  Drugs       Date:  2014-03       Impact factor: 9.546

Review 9.  Hypertension in pregnancy: a review of therapeutic options.

Authors:  D Kernaghan; A C Duncan; G A McKay
Journal:  Obstet Med       Date:  2012-02-17

Review 10.  Report of the Canadian Hypertension Society Consensus Conference: 3. Pharmacologic treatment of hypertensive disorders in pregnancy.

Authors:  E Rey; J LeLorier; E Burgess; I R Lange; L Leduc
Journal:  CMAJ       Date:  1997-11-01       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.